Results 91 to 100 of about 256 (108)

Investigating MARK4 inhibitory potential of Bacopaside II: Targeting Alzheimer's disease

International Journal of Biological Macromolecules, 2023
Microtubule affinity regulating kinase 4 (MARK4) is known to hyperphosphorylate tau protein, which subsequently causes Alzheimer's disease (AD). MARK4 is a well-validated drug target for AD; thus, we employed its structural features to discover potential inhibitors.
Saleha Anwar, Taj Mohammad, Gulam Mustafa Hasan   +2 more
exaly   +3 more sources

ChemInform Abstract: Bacopaside I and II: Two Pseudojujubogenin Glycosides from Bacopa monniera.

ChemInform, 2002
AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
Ajit K. Chakravarty, Tapas Sarkar, Kazuo Masuda, Kenji Shiojima, Takahisa Nakane, Nobuo Kawahara   +5 more
openaire   +2 more sources

Corrigendum to “Bacopaside I and II: two pseudojujubogenin glycosides from Bacopa monniera” [Phytochemistry 58 (2001) 553–556]

Phytochemistry, 2002
Ajit K Chakravarty, Tapas Sarkar, Kazuo Masuda, Kenji Shiojima, Takahisa Nakane, Nobuo Kawahara   +5 more
openaire   +2 more sources

Insights Into the Molecular Aspects of Neuroprotective Bacoside A and Bacopaside I

Current Neuropharmacology, 2019
Bacopa monnieri, commonly known as Brahmi, has been extensively used as a neuromedicine for various disorders such as anxiety, depression and memory loss.
Vini C Sekhar, Gayathri Viswanathan, Sabulal Baby   +2 more
exaly   +2 more sources

Molecular mechanisms of aquaporin 1 inhibition by Bacopaside I and Bacopaside II: Insights from molecular dynamics simulations

Journal of Molecular Graphics and Modelling
Aquaporin-1 (AQP1),a key water channel protein, is aberrantly overexpressed in multiple malignancies, rendering it a compelling therapeutic target. The natural products Bacopaside I and Bacopaside II have demonstrated inhibitory activity against AQP1, yet their molecular mechanisms remain elusive.
Mingyu Wei, Zien Yu, Chi Huang, Shuwei Han, Sitian Zhou, Ting Wang, Shibin Chang, Xiaoying Chen, Feisheng Zhong, Shaojie Ma   +9 more
openaire   +2 more sources

In Vitro Synergistic Inhibition of HT-29 Proliferation and 2H-11 and HUVEC Tubulogenesis by Bacopaside I and II Is Associated with Ca2+ Flux and Loss of Plasma Membrane Integrity

Pharmaceuticals, 2021
Yoko Tomita, Eric Smith, Helen M Palethorpe   +2 more
exaly  

An enzyme-linked immunosorbant assay using polyclonal antibodies against bacopaside I

Analytica Chimica Acta, 2007
Watoo Phrompittayarat, Waraporn Putalun, Sakchai Wittaya-Areekul   +2 more
exaly  

Stability Studies of Crude Plant Material of Bacopa monnieri and Quantitative Determination of Bacopaside I and Bacoside A by HPLC

Phytochemical Analysis, 2012
Pratibha Srivastava
exaly  

Bacopaside N1 biosynthetic potential of endophytic Aspergillus sp. BmF 16 isolated from Bacopa monnieri

3 Biotech, 2017
B Jasim, R Aswani, Mathew Jyothis
exaly  

Determination of pseudojujubogenin glycosides from Brahmi based on immunoassay using a monoclonal antibody against bacopaside I

Phytochemical Analysis, 2007
Watoo Phrompittayarat, Waraporn Putalun, Sakchai Wittaya-Areekul   +2 more
exaly